Mendelspod Podcast

There’s a new genome editing company that everyone is talking about this year.  Tome Biosciences came out of stealth in December, claiming the ability to insert DNA sequences of any size at any locat…

0:00 Long reads at scale has made what difference?6:15 The long or short of it:  How does one decide?12:31 Long…

Why aren’t more folks receiving genetic testing?In a study published in JAMA last year, Stanford cancer researcher Alison Kurian found a surprising gap between those who need genetic testing and thos…

Batten disease is a group of neurodegenerative lysosomal storage disorders that result from pathogenic variants in one of 13 CLN genes. Collectively, Batten disease affects approximately 1 in 100,000…

After ten years, the human brain mapping project has achieved some major milestones, says Tom Nowakowski, a researcher at UCSF, on today’s program.  He says that mapping the brain is a “moon shot” ea…

Karen Tumulty, a political writer for the Washington Post, was diagnosed with multiple myeloma. She was told she had five years to live.  Then she went to book club with friends. On the way home she …

Fun fact:  we are composed of 90% bacterial cells and 10% human cells.  Surely, the company that begins to turn that kn…

"We can now begin to look at disease before it happens,” says today’s guest, Todd Druley.  He’s the Chief Medical Offic…

This month, the FDA approved the first CRISPR-based gene therapy called Casgevy (pronounced with a soft g). It’s a one-and-done treatment for sickle cell disease and is being hailed as major step fo…

Many of our shows this year have explored a new wave of proteomics tools and research.  So today, we wanted to get a sn…

This month, a new philosophy of biology series premiers on PBS hosted by Robert Lawrence Kuhn.  The series will go for …

John Shon is the Chief Technology Officer at Serimmune, a company specializing in precision immunology.  Serimmune main…

Our guest today introduced us to a new kind of immunotherapy called Super-NK.  Imagine CAR-T, but in this case, the immune cells from the patient are not engineered, but rather “supercharged.”  What’…

Personalis, a company launched during the early days of whole genome testing and analysis, is claiming to have the most…

Chapters:

0:00 Delivering on last year’s announcements

8:50 Illumina

14:25 Long reads

25:50 PacBio vs Oxford Nano…

Chapters:

0:00   State of the field: reviewing ICoNS conference

22:20 What evidence is enough?

Today, we’re joined by a panel of four guests who have all attended the recent International Conference…

Chapters:0:00 Precision oncology is standard of care13:50 Culmination Bio23:25 Hopeful about early cancer screenin…

Chapters:0:00 What are transcription factors?7:00 The MARMOT platform11:22 In the ’90s, people thought kinas…

Chapters:0:00 Attending this year’s Human Proteome Organization (HUPO) conference4:40 Mass spec vs. sequencing8:1…

Chapters:0:00 What does treatment look like?7:25 Light treatment has been approved for years20:10 Could this …